Changchun High-Tech: Subsidiary Injectible GenSci143 Overseas Production Drug Registration Clinical Trial Application Approved.

Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has received approval for clinical trial application of the injectable GenSci143 in the United States. GenSci143 is a bispecific antibody-drug conjugate independently developed by Jinsai Pharmaceutical, intended for the treatment of various late-stage solid tumors such as prostate cancer and lung cancer. Previously, GenSci143 has been approved in China for clinical trials in late-stage solid tumors.